Research programme: ECM protein modulators - 3B Pharmaceuticals
Latest Information Update: 13 Jan 2014
At a glance
- Originator 3B Pharmaceuticals
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Extracellular matrix protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 13 Jan 2014 Early research in Solid tumours in Germany (unspecified route)
- 13 Jan 2014 Early research in Solid tumours (diagnosis) in Germany (unspecified route)